Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Withdrawn Phase 1Phase 2 Interventional

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

NCT04787250
View directory record Official record
Conditions
Prosthetic Joint Infection
Interventions
Phage Therapy, Two-Stage Exchange Arthroplasty
Biological · Procedure
Lead sponsor
Adaptive Phage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 30, 2026, 1:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

NCT07730450
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
BNT162b2 Vaccine, Tdap Vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit

NCT03440918
View directory record Official record
Conditions
Sepsis, Procalcitonin, Antimicrobial Stewardship
Interventions
Procalcitonin-Guided Antimicrobial Stewardship, Baseline Antimicrobial Stewardship
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Hours to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Results available

Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients

NCT01619982
View directory record Official record
Conditions
Congenital Heart Diseases, Aortic Valve Disorder
Interventions
Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride, Cefazolin 30 mg/kg body weight
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

NCT00634959
View directory record Official record
Conditions
HIV
Interventions
Maraviroc (UK-427,857), Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection

NCT00513461
View directory record Official record
Conditions
Adult Primary Liver Cancer, Hepatitis C Infection
Interventions
S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis, immunoenzyme technique, high performance liquid chromatography
Drug · Other
Lead sponsor
Chao Family Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 30, 2026, 1:48 PM EDT
Completed No phase listed Observational

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 30, 2026, 1:48 PM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 30, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Infection Prophylaxis Prior to Shoulder Surgery

NCT06464770
View directory record Official record
Conditions
Arthroplasty Shoulder, Periprosthetic Joint Infection
Interventions
Chlorhexidine Gluconate
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Juntos/Together Program to Build Confidence for Complex Care Tasks Among Latino Family Caregivers

NCT05582473
View directory record Official record
Conditions
Dementia Caregivers
Interventions
LST-LC Education
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

NCT02065973
View directory record Official record
Conditions
High-risk HPV Infection and Biopsy-proven CIN1
Interventions
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
Biological
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Port Jefferson, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 30, 2026, 1:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bladder Botox UTI Antibiotic Prophylaxis

NCT06387329
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome
Interventions
Nitrofurantoin 100 MG
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 30, 2026, 1:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays

NCT06607003
View directory record Official record
Conditions
Malaria
Interventions
P. vivax challenge agent derived from PvHMB-CCE001
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 54 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Results available

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

NCT03354754
View directory record Official record
Conditions
Intra-abdominal Infections
Interventions
LYS228, Standard of care therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Somers Point, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS

NCT00002294
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 4 Interventional

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

NCT00002179
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

NCT05566379
View directory record Official record
Conditions
Long COVID, Dysautonomia
Interventions
Mindfulness - Mindful Awareness Practices ( MAPs)
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 30, 2026, 1:48 PM EDT
Terminated No phase listed Observational

Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing

NCT03271580
View directory record Official record
Conditions
Wound, Bacterial Infections, Diabetes Mellitus, Infected Ulcer of Skin
Interventions
Finger prick test for HbA1c measurement, Punch Biopsy, Vac Sponge Collection, Ankle Brachial Index
Diagnostic Test · Procedure · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Indianapolis, Indiana • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03005327
View directory record Official record
Conditions
WHIM Syndrome
Interventions
X4P-001
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Study of Prophylactic Vs Preemptive Valganciclovir

NCT00374686
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 30, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

NCT03762473
View directory record Official record
Conditions
Renal Transplant Infection
Interventions
Study Group, Control Group
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 30, 2026, 1:48 PM EDT
Not listed No phase listed Observational

DETEC® Esterase for Screening Wound Infection at Point of Care

NCT04614870
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
Interventions
DETEC® Esterase
Diagnostic Test
Lead sponsor
Progenitec Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 30, 2026, 1:48 PM EDT